Sergio A. Giralt, MD, discusses how the pathophysiology of chronic graft-vs-host disease involves complex immune dysregulation, with CSF1R playing a crucial role in driving the differentiation of ...
An allogeneic hematopoietic stem cell transplantation that triggers graft-vs.-host-disease (GVHD) involves T cells that do not come from the patient's bloodstream, but rather from the local progenitor ...
A recent study by a team led by Professor Shin Kaneko successfully induced regulatory T cell (Treg)-like cells from iPS cell-derived conventional helper T cells (Tconvs) and demonstrated their ability ...
It’s possible to manage graft-versus-host disease (GVHD) with appropriate treatments. Your individualized treatment plan will depend on your symptoms, their severity, and the disease’s response to ...
SEATTLE — With increasing survival rates after allogeneic hematopoietic stem cell transplantation (HSCT) in children, dermatologists may be seeing more skin conditions associated with HSCT, including ...
The European Medicines Agency (EMA) has recommended the refusal of marketing authorization for Rezurock (belumosudil) for treating patients 12 years or older with chronic graft-vs-host disease (cGvHD) ...
Discusses Phase II Acute Graft Versus Host Disease and Phase III Osteoarthritis Trial Results June 21, 2026 6:30 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results